![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ALANTOS BEGINS STUDY OF DIABETES DRUG
ALANTOS BEGINS STUDY OF DIABETES DRUG
Alantos Pharmaceuticals has initiated a Phase I study of ALS 2-0426, an orally active, small-molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV) for the treatment of Type 2 diabetes.
Designed in two parts, the double-blind, placebo-controlled study will enroll approximately 50 healthy male volunteers in one center in the U.S. The first study uses a single, ascending oral dose and sequential cohort design and will be followed by a multiple-dose study also in healthy volunteers. The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ALS 2-0426.
DPP-IV inactivates glucagon-like peptide-1, an important mediator of blood glucose levels following meals. DPP-IV inhibitors have been clinically shown to provide long-term improvement of glucose control without the risk of hypoglycemia, and to improve the function of pancreatic beta cells, the cells responsible for the production of insulin.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct